
Lebrikizumab shows up to 4 years of sustained control in moderate-to-severe atopic dermatitis
Lebrikizumab provides up to four years of sustained disease control in moderate-to-severe atopic dermatitis Lebrikizumab Almirall, a global biopharmaceutical company dedicated to advancing medical dermatology, has announced encouraging long-term interim results from its ongoing Phase 3b ADlong clinical trial evaluating…












